MOVANTIK® Brought to Market in Canada by Knight Therapeutics

Knight obtained the exclusive license to market and sell MOVANTIK in Canada from AstraZeneca

Knight Therapeutics Inc. recently announced the commercial relaunch of MOVANTIK, which is used to treat OIC in adult patients with non-cancer pain who have had an inadequate response to laxatives.

"MOVANTIK represents our first commercial specialty product in Canada," said Jonathan Ross Goodman, CEO of Knight Therapeutics Inc. "MOVANTIK's targeted mechanism of action offers an additional therapeutic option for healthcare professionals managing patients with OIC and it fits seamlessly with Knight's portfolio of pain supportive therapeutics."

NewsCatherine Lamontagneknight, movantik, license, canadian market, OIC